[New pneumococcal vaccine].Bull Acad Natl Med. 2003; 187(8):1477-86; discussion 1486-8.BA
Streptococcus Pneumoniae is the main pathogen bacteria responsible for invasive diseases (bacteremia, meningitis) in children less than 2 years of age. The new conjugate heptavalent pneumococcal vaccine (7 polysaccharide serotypes 4, 6B, 9V, 14, 18C, 19F, 23F conjugated with the CRP 197 protein derived from diphteria anatoxin) is a great advance. This vaccine is well tolerated, immunogenic and efficient in infant. His efficacy in invasive pneumococcal diseases is more than 95%. The reduction of pneumonia (with 2.5 cm X-Ray opacity) was 32.2% in the first year of age and 23.4% in the two first years in the vaccinated group. The efficacy in acute otitis media is poor French indications of this vaccine, limited to infants under 2 years of age with further risk factor, might be extended to all the infants under 2 years of age.